Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SXTP
stocks logo

SXTP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
300.00K
+140.06%
-1.280
-93.77%
400.00K
+195.66%
-1.380
-68.19%
400.00K
+65.54%
-1.340
-84.2%
Estimates Revision
The market is revising No Change the revenue expectations for 60 Degrees Pharmaceuticals, Inc. (SXTP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -30.49%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-30.49%
In Past 3 Month
Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 0.980
sliders
Low
3.40
Averages
3.40
High
3.40
Current: 0.980
sliders
Low
3.40
Averages
3.40
High
3.40
H.C. Wainwright
Buy
initiated
$6
2025-11-14
Reason
H.C. Wainwright
Price Target
$6
2025-11-14
initiated
Buy
Reason
H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals with a Buy rating and $6 price target. The firm says 60 Degrees is "flying under the radar with investors." Tafenoquine is a differentiated, FDA approved product that is already on the market and has demonstrated "impressive" initial clinical activity in babesiosis, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-28
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-01-10
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-01-10
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-12-23
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-12-23
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-12-11
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-12-11
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP.O) is -0.59, compared to its 5-year average forward P/E of -0.88. For a more detailed relative valuation and DCF analysis to assess 60 Degrees Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.88
Current PE
-0.59
Overvalued PE
-0.02
Undervalued PE
-1.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.85
Current PS
2.65
Overvalued PS
10.60
Undervalued PS
-0.91
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SXTP News & Events

Events Timeline

(ET)
2025-11-21
08:14:57
60 Degrees Reveals Central Location for B-FREE Study Now Accepting Patient Enrollments
select
2025-11-13 (ET)
2025-11-13
13:56:22
60 Degrees Pharmaceuticals Announces Q3 EPS of 66 Cents Compared to a Loss of $4.65 Last Year
select
2025-10-15 (ET)
2025-10-15
07:17:05
60 Degrees Reports First Patient Successfully Completes Babesiosis Trial Regimen
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-28Benzinga
Dick's Sporting Goods Set to Surge by 17%? Check Out 10 Leading Analyst Predictions for Friday

  • Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets for various companies, with notable changes including Ascendiant Capital lowering 60 Degrees Pharmaceuticals' target from $3 to $2.8 while maintaining a Buy rating.

  • Price Target Increases: UBS raised the price target for Five Below from $184 to $204, and Telsey Advisory Group increased Macy's target from $17 to $22, both maintaining Buy or Market Perform ratings.

  • Price Target Decreases: JP Morgan cut the price target for Cabot Corp from $75 to $54 and Orion SA from $9 to $5, both maintaining Underweight ratings.

  • Mixed Ratings: Barclays adjusted targets for several companies, including raising Abercrombie & Fitch's target from $84 to $94 while maintaining an Equal-Weight rating, and cutting Dick’s Sporting Goods' target from $246 to $242 but keeping an Overweight rating.

[object Object]
Preview
6.0
11-28Benzinga
Ascendiant Capital Reaffirms Buy Rating on 60 Degrees, Adjusts Price Target to $2.8

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
9.0
11-22Yahoo Finance
60 Degrees Launches Central Location for Patient Enrollment in B-FREE Study

  • Study Announcement: 60 Degrees Pharmaceuticals has opened patient enrollment for its B-FREE Chronic Babesiosis Study at the Cohen Center for Recovery from Complex Chronic Diseases, marking the first evaluation of a therapeutic for chronic babesiosis.

  • Study Details: The Phase 2 open-label study will assess the efficacy of the ARAKODA regimen of tafenoquine over 90 days, focusing on resolving severe fatigue and eradicating parasites in patients with chronic babesiosis.

  • Chronic Babesiosis Definition: Chronic babesiosis is characterized by disabling fatigue lasting at least six months, accompanied by other symptoms and laboratory confirmation of Babesia parasite exposure within the last year.

  • Regulatory Status: To date, no treatment for babesiosis has been approved by the U.S. Food and Drug Administration.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?

The current price of SXTP is 0.9801 USD — it has decreased -3.92 % in the last trading day.

arrow icon

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s business?

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

arrow icon

What is the price predicton of SXTP Stock?

Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s revenue for the last quarter?

60 Degrees Pharmaceuticals Inc revenue for the last quarter amounts to 256.28K USD, increased 75.42 % YoY.

arrow icon

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s earnings per share (EPS) for the last quarter?

60 Degrees Pharmaceuticals Inc. EPS for the last quarter amounts to -1.55 USD, decreased -183.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for 60 Degrees Pharmaceuticals Inc (SXTP)'s fundamentals?

The market is revising No Change the revenue expectations for 60 Degrees Pharmaceuticals, Inc. (SXTP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -30.49%.
arrow icon

How many employees does 60 Degrees Pharmaceuticals Inc (SXTP). have?

60 Degrees Pharmaceuticals Inc (SXTP) has 3 emplpoyees as of December 05 2025.

arrow icon

What is 60 Degrees Pharmaceuticals Inc (SXTP) market cap?

Today SXTP has the market capitalization of 3.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free